Results 181 to 190 of about 119,167 (297)

Twenty‐Four Month Outcomes From a Real‐World Telehealth Obesity Treatment Clinic Using Obesity Medications

Obesity, EarlyView.
ABSTRACT Objective Antiobesity medications (AOMs) are indicated for long‐term use; however, evidence of their real‐world long‐term efficacy is limited. This study describes clinical outcomes from 18‐ and 24‐month use of AOMs in a telemedicine weight management clinic.
Kathleen R. Ruddiman, Young‐Rock Hong, Jamy Ard, Rebecca Jones, Adam Medcalf, Gary D. Foster, Jamil Alkhaddo, Michelle Cardel   +7 more
wiley   +1 more source

Dysfunctional Lipid-Induced Secretion of Glucagon-Like Peptide-2(GLP-2), but Not of Incretins Glucagon-Like Peptide-1(GLP-1)/Glucose-Dependent Insulinotropic Polypeptide(GIP), Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia. [PDF]

MedComm (2020)
Musso G, Pinach S, Mella A, De Michieli F, Calabrese A, Trifiro D, Petrangolini G, Cassader M, Mariano F, Gambino R.   +9 more
europepmc   +1 more source

Weight Loss With GLP‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective Two glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) (semaglutide and liraglutide) and one dual agonist (tirzepatide) are FDA‐approved for weight loss in adults with obesity without type 2 diabetes mellitus. This systematic review and network meta‐analysis aims to compare the efficacy of these agents against each other.
Michael Lim, Pooja Gokhale, Akwasi Akosah, Lorenzo Villa‐Zapata   +3 more
wiley   +1 more source

Glucagon-like Peptide-2 Acts Partially Through Central GLP-2R and MC4R in Mobilizing Stored Lipids from the Intestine. [PDF]

Nutrients
Mukherjee K, Khan MSA, Howland JG, Xiao C.   +3 more
europepmc   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

Effect of teduglutide, a glucagon-like peptide-2 analog, in eosinophilic enterocolitis: a case report. [PDF]

Front Pediatr
Ogawa S, Konishi KI, Tanaka K, Takayasu H, Uematsu Y, Ito T, Takahashi H, Kumamoto Y.   +7 more
europepmc   +1 more source

The Possible Involvement of Glucagon-like Peptide-2 in the Regulation of Food Intake through the Gut-Brain Axis. [PDF]

Nutrients
Baccari MC, Vannucchi MG, Idrizaj E.
europepmc   +1 more source

Parental Communication With Children Around Obesity Management Medications, Weight Loss, and Health Behavior Change

Obesity, EarlyView.
ABSTRACT Objective This study aimed to describe parental communication with children around obesity management medications (OMMs) and child, parent, and family factors associated with communication. Methods Parents (N = 211; 80% mothers; 89% White) prescribed OMMs at a medical center participated in a survey about communication with children about OMM ...
Keeley J. Pratt, Selena Gonzlez‐Jordan, Sabrena F. Noria, Joseph A. Skelton   +3 more
wiley   +1 more source

Development of a Mechanism of Action-Reflective Cell-Based Reporter Gene Assay for Measuring Bioactivities of Therapeutic Glucagon-like Peptide-2 Analogues. [PDF]

Molecules
Zhang X, Li C, Deng Z, Liang C, Li J.
europepmc   +1 more source

Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER‐Medicare 2007–2015

Obesity, EarlyView.
ABSTRACT Objective This study evaluated the association between antiobesity medications (AOM) and incident cardiovascular disease (CVD) among older women, examining this relationship within and across survivors of obesity‐related cancers (ORCa) and age‐matched cancer‐free populations.
David S. Lopez, Omer Abdelgadir, Yuanyi Zhang, Jesús Gibran Hernández‐Pérez, Maryam R. Hussain, Mohanad Albayyaa, Rasmi Nair, Yong‐Fang Kuo, Jaime P. Almandoz, Lindsay G. Cowell, Sarah E. Messiah   +10 more
wiley   +1 more source